Clinical Trial Update: Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease [Phase 4]

View source ↗

Summary

Phase 4 trial assessing efficacy and cost-effectiveness of cost-free pharmacotherapy for smoking cessation in high-risk smokers with cerebrovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebrovascular Disorders
• Smoking Cessation

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: Cerebrovascular Disorders, Smoking Cessation | Phase 4 | Status: COMPLETED